← Back to guidelines
Allergy & Immunology6 papers

Hemolytic anemia caused by Clostridium welchii

Last edited: 4/15/2026

Overview

Hemolytic anemia caused by Clostridium welchii (also known as Clostridium perfringens) typically results from an immune response to bacterial toxins or direct hemolysin activity, leading to intravascular hemolysis and potentially severe clinical manifestations [Not directly addressed in provided abstracts].

Diagnosis

  • Clinical Presentation: Symptoms may include acute onset of anemia, jaundice, hemoglobinuria, and potentially disseminated intravascular coagulation (DIC) [Not directly addressed in provided abstracts].
  • Laboratory Tests: Elevated lactate dehydrogenase (LDH), indirect bilirubin, and reticulocyte count; peripheral blood smear may show schistocytes indicating microangiopathic hemolysis [Not directly addressed in provided abstracts].
  • Culture and Sensitivity: Stool or tissue cultures may identify Clostridium welchii, though not always definitive in clinical settings [Not directly addressed in provided abstracts].
  • Management

  • Supportive Care: Fluid resuscitation, blood transfusions as needed for severe anemia [Not directly addressed in provided abstracts].
  • Antitoxin Therapy: Administration of specific antitoxins if available; however, specific drug classes and doses are not detailed in the provided abstracts [Not directly addressed in provided abstracts].
  • Antibiotics: Targeted therapy against Clostridium species, such as penicillin or metronidazole, based on sensitivity patterns [Not directly addressed in provided abstracts].
  • Special Populations

  • Pregnancy: Specific management considerations for pregnant women are not detailed in the provided abstracts [Not directly addressed in provided abstracts].
  • Pediatrics: Pediatric-specific dosing and management strategies are not covered in the abstracts [Not directly addressed in provided abstracts].
  • Elderly: No specific guidelines or considerations for elderly patients are mentioned [Not directly addressed in provided abstracts].
  • Comorbidities: Management adjustments for patients with comorbidities like renal failure or coagulopathies are not addressed [Not directly addressed in provided abstracts].
  • Key Recommendations

  • Initiate supportive care including fluid resuscitation and blood transfusions for severe anemia (Evidence: Expert opinion) [Not directly addressed in provided abstracts].
  • Administer antitoxins if available, though specific dosing is not detailed (Evidence: Expert opinion) [Not directly addressed in provided abstracts].
  • Use antibiotics effective against Clostridium species based on sensitivity testing (Evidence: Expert opinion) [Not directly addressed in provided abstracts].
  • References

    1 Ali MK, Fukumura M, Sakano K, Karita S, Kimura T, Sakka K et al.. Cloning, sequencing, and expression of the gene encoding the Clostridium stercorarium xylanase C in Escherichia coli. Bioscience, biotechnology, and biochemistry 1999. link

    Original source

    1. [1]
      Cloning, sequencing, and expression of the gene encoding the Clostridium stercorarium xylanase C in Escherichia coli.Ali MK, Fukumura M, Sakano K, Karita S, Kimura T, Sakka K et al. Bioscience, biotechnology, and biochemistry (1999)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG